|
Cancer Biotherapy & Radiopharmaceuticals
Use of Galactosylated-Streptavidin as a Clearing Agent with 111In-Labeled, Biotinylated Antibodies to Enhance Tumor/Non-Tumor Localization Ratios
To cite this article:
Serengulam V. Govindan, Gary L. Griffiths, Rosana B. Michel, Philip M. Andrews, David M. Goldenberg, M. Jules Mattes.
Cancer Biotherapy & Radiopharmaceuticals.
June 2002,
17(3): 307-316.
doi:10.1089/10849780260179279.
Serengulam V. Govindan Immunomedics, Inc., Morris Plains, New Jersey Gary L. Griffiths Immunomedics, Inc., Morris Plains, New Jersey Rosana B. Michel Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, New Jersey Philip M. Andrews Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, New Jersey David M. Goldenberg Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, New Jersey M. Jules Mattes Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, New Jersey Optimal tumor imaging using radiolabeled antibodies (Abs) depends on obtaining the highest possible tumor/non-tumor localization ratios. To increase this ratio, in a mouse xenograft model system, we induced rapid blood clearance of the Ab after extensive penetration of a solid tumor, at 24 hr after Ab injection. By using galactosylated streptavidin (gal-SA) as a clearing agent for biotinylated Abs, and by using an 111In-DTPA (diethylenetriaminepentaacetic acid) label, clearance was directed to hepatocytes (as opposed to Kupffer cells), and the radiolabel was excreted by the hepatocytes into bile, thereby reducing accumulation in the liver. In this study, we directly compared this approach with the use of 99mTc-F(ab)2 fragments, using the same Ab to carcinoembryonic antigen (CEA), with a colon carcinoma xenograft. The gal-SA clearance method produced substantially higher tumor/non-tumor localization ratios for all tissues except the liver, and even for the liver the disadvantage of the gal-SA clearance method was small. We also tested the gal-SA clearance method with a xenograft model of human B-cell lymphoma, using anti-CD22. High tumor/non-tumor ratios were obtained, as previously described with carcinomas of the lung and colon. Therefore, this approach appears to be a generally applicable strategy to obtain relatively high tumor/non-tumor ratios.  This paper was cited by:Comparative Biodistribution of Potential Anti- Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice Vladimir Tolmachev, Anna Orlova, Qichun Wei, Alexander Bruskin, Jörgen Carlsson, Lars Gedda Cancer Biotherapy & Radiopharmaceuticals. Aug 2004, Vol. 19, No. 4: 491-502 Abstract | Full Text PDF | Reprints & Permissions[177Lu]Bz-DTPA-EGF: Preclinical Characterization of a Potential Radionuclide Targeting Agent Against Glioma Åsa Liljegren Sundberg, Lars Gedda, Anna Orlova, Alexander Bruskin, Erik Blomquist, Jörgen Carlsson, Vladimir Tolmachev Cancer Biotherapy & Radiopharmaceuticals. Apr 2004, Vol. 19, No. 2: 195-204 Abstract | Full Text PDF | Reprints & Permissions
|
|